The CX Venous Workshop returned on Wednesday, bigger than ever before. With a new location in the Exhibition Hall and its own series of edited live case presentations, it continues to showcase innovative venous technology and offer delegates the chance to get hands-on with the latest advances in the arena. Expanding from previous years’ Venous Village to this year’s Venous City, the workshop has brought together delegates and demonstrators from all over the world to experience the state of the art.
For the first time, Day One of this year’s CX Venous Workshop included two edited case presentations (CX Venous Edited Cases). The standing-room only session gave delegates the opportunity to watch two innovative devices in action and quiz experienced surgeons on their top procedural tips.
First-time data presentation from the SWAN (Screening Women for Abdominal aNeurysms) project was heard at the 2017 Charing Cross Symposium (CX; 25–28 April, London, UK). The study, which used simulation to evaluate whether inviting women to be screened for abdominal aortic aneurysm would have clinical benefit, or be cost-effective, revealed that such a programme would yield a very small benefit. Further, such a screening programme would not be cost-effective in the UK context.
A “podium first” presentation of very long-term follow-up data from the EVAR 2 trials suggests that endovascular aneurysm repair (EVAR) fails to improve all-cause mortality, but reduces aneurysm-related mortality compared to no treatment in abdominal aortic aneurysm patients who are physically ineligible for open repair. The data were presented yesterday at CX and prompted a discussion on the dilemma of whether to offer, or withhold, EVAR in this group of frail patients in the light of these findings. The panel discussion then prompted a spontaneous show of hands in which delegates backed the idea of adopting a model of shared decision-making with frail patients who are in poor health when discussing EVAR or no treatment.
Medtronic has reported that its Endurant II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a real-world setting. The five-year ENGAGE global registry data were presented for the first time at the 2017 CX Symposium in London, UK.
At the 2017 Charing Cross Symposium (CX; 25–28 April, London, UK), delegates heard brand new data for drug-coated balloons (DCBs) in “wider use” scenarios such as challenging lesions; one-year results for a novel DCB; and late-breaking data on downstream coating effects of various DCBs. Still, 84% of the CX audience said “no” in response to the question: are DCBs equally effective in all lesion subsets? There is still uncertainty in the therapeutic puzzle about which device in the endovascular armamentarium is best suited to treat which lesion.
Tuesday’s CX Aortic Edited Cases session featured exciting and engaging standing-room only case presentations, including Andrew Holden’s (Auckland, New Zealand) first-in-man implantation of the Ovation Alto (Endologix). Covering thoracic, juxtarenal and abdominal cases, the packed-out session explored innovative techniques, novel devices and a veritable array of practical tips and tricks, offering an invaluable resource for delegates.
Lombard Medical has now enrolled and treated the first patient in its global registry to evaluate its Altura endograft system.
The particular complexities of dealing with paediatric vessels were discussed in depth at Tuesday’s varied and informative CX Paediatric Vascular Emergencies and Case Presentations session. Covering topics as diverse as acute ischaemia from pre-term to infant and treatment for battlefield trauma in children, the session was one of the highlights of the day.
In Tuesday’s CX Congenital Vascular Malformations session, delegates heard about how approaching congenital vascular malformations with systematic pathways of care and classification systems can greatly assist physicians in achieving consistently successful positive outcomes.
Getinge has announced that, in order to better convey its customer offering and strengthen its position, it has grouped its portfolio under one single brand – Getinge. The company has also now launched the Advanta V12 32mm balloon-expandable covered stent.
Bluegrass Vascular Technologies has enrolled over one third of its patients in the company’s post-market SAVE (Surfacer System to Facilitate Access in Venous Occlusions) clinical study. The SAVE study is an international, prospective, multicentre clinical follow-up study designed to confirm clinical performance and safety of the Surfacer inside-out access catheter system, a device indicated for obtaining central venous access to facilitate catheter insertion into the central venous system in patients with chronically occluded veins.
Ra Medical Systems and bo medical technologies, have announced the launch of the Dabra atherectomy system for cardiovascular and Pharos excimer laser for dermatology in Europe.
PinnacleHealth CardioVascular Institute has enrolled the first US patient in a trial assessing the safety and effectiveness of a new type of approach for blockages in the leg artery.
QXMédical has announced its sponsorship of EVARplanning.com, an online tool which helps vascular and cardiovascular specialists plan complex endovascular aneurysm repair (EVAR) procedures.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos